Depiperazine-DM3189
Depiperazine-DM3189 is a derivative of LDN193189. LDN193189 is a potent selective BMP type I receptor (BMP I) inhibitor. LDN-193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 values of 5 nM and 30 nM, respectively. LDN-193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva[1][2][3].
Product Specifications
CAS Number
1062368-55-1
Product Name Alternative
Depiperazine-LDN-193189
Target
Drug Derivative; TGF-beta/Smad
Related Pathways
Others; Stem Cell/Wnt; TGF-beta/Smad
Field of Research
Cancer
Smiles
C1(C2=C3N=CC(C4=CC=CC=C4)=CN3N=C2)=CC=NC5=CC=CC=C15
Molecular Formula
C21H14N4
Molecular Weight
322.36
References & Citations
[1]Yu PB, et al. BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat Med, 2008, 14 (12), 1363-1369. |[2]Daniel Horbelt, et al. Small molecules dorsomorphin and LDN-193189 inhibit myostatin/GDF8 signaling and promote functional myoblast differentiation. J Biol Chem. 2015 Feb 6;290 (6) :3390-404. |[3]Julien Vollaire, et al. The Bone Morphogenetic Protein Signaling Inhibitor LDN-193189 Enhances Metastasis Development in Mice. Front Pharmacol. 2019 Jun 19;10:667.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
